Keywords: Astellas, Ipragliflozin, Type 2 diabetes, Japan, Regulatory filing
Astellas files for Japanese approval of ipragliflozin for types 2 diabetes
Article | 14 March 2013
Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for a SGLT2 inhibitor ipragliflozin (development code: ASP1941) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
